Nanomedicines for HIV therapy.
Heterogeneity in response to HIV treatments has been attributed to several causes including variability in pharmacokinetic exposure. Nanomedicine applications have a variety of advantages compared with traditional formulations, such as the potential to increase bioavailability and specifically target the site of action. Our group is focusing on the development of nanoformulations using a closed-loop design process in which nanoparticle optimization (disposition, activity and safety) is a continuous process based on experimental pharmacological data from in vitro and in vivo models. Solid drug nanoparticles, polymer-based drug-delivery carriers as well as nanoemulsions are nanomedicine options with potential application to improve antiretroviral deployment.
Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, UK. siccardi@liverpool.ac.uk
Marco
M
Siccardi
Philip
P
Martin
Tom O
TO
McDonald
Neill J
NJ
Liptrott
Marco
M
Giardiello
Steve
S
Rannard
Andrew
A
Owen
D000818:Animals; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001682:Biological Availability; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D015195:Drug Design; D004655:Emulsions; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008954:Models, Biological; D050997:Nanomedicine; D053758:Nanoparticles; D011108:Polymers / Q000737:chemistry
D019380:Anti-HIV Agents; D004337:Drug Carriers; D004655:Emulsions; D011108:Polymers